Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis Report 2026

Report Coverage

The Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis Report by Expert Market Research gives comprehensive insights into relapsed or refractory myelodysplastic syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for relapsed or refractory myelodysplastic syndrome. The relapsed or refractory myelodysplastic syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The relapsed or refractory myelodysplastic syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with relapsed or refractory myelodysplastic syndrome treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to relapsed or refractory myelodysplastic syndrome.

Read more about this report - Request a Free Sample

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Outlook

Relapsed or refractory myelodysplastic syndrome (R/R MDS) is a high-risk hematologic malignancy characterized by ineffective blood cell production and progression after initial therapy. It occurs when patients fail to respond to, or relapse after, standard hypomethylating agents, often due to clonal evolution, genetic instability, and acquired drug resistance, leading to rapid disease progression and poor survival outcomes.

Relapsed or refractory myelodysplastic syndrome treatment focuses on disease control after hypomethylating agent failure and includes combination therapies, targeted immunotherapies, clinical trial agents, supportive care, and allogeneic stem cell transplantation in eligible patients to improve response rates and extend survival. In August 2024, Faron Pharmaceuticals Ltd. received United States Food and Drug Administration Fast Track Designation for bexmarilimab in combination with azacitidine for relapsed or refractory myelodysplastic syndrome. The designation followed promising Phase I and Phase II BEXMAB trial results demonstrating clinically meaningful responses in hypomethylating agent–resistant patients.

Relapsed or Refractory Myelodysplastic Syndrome Epidemiology

The pipeline underscores the growing disease burden with limited durable treatment options. According to Guillermo Garcia-Manero et al., 2023, myelodysplastic syndrome prevalence in the United States rises sharply with age, reaching 7-35 cases per 100,000 individuals aged 60 years and above. As per Xinyue Gou et al., 2025, the global burden of myelodysplastic syndrome and myeloproliferative neoplasm increased steadily from 1990 to 2021, driven mainly by population growth. The median age at diagnosis in the United States is 76 years, with a reported three-year survival rate of only 35%, reinforcing the need for advanced therapeutic development.

Relapsed or Refractory Myelodysplastic Syndrome – Pipeline Therapeutic Assessment

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I, with 65%, covers a major share of the total Relapsed or Refractory Myelodysplastic Syndrome clinical trials, reflecting strong early clinical innovation. Phase II holds 33%, indicating steady mid-stage progression. Collectively, this balanced phase distribution supports sustained pipeline momentum and future market growth.

Relapsed or Refractory Myelodysplastic Syndrome Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the relapsed or refractory myelodysplastic syndrome pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The relapsed or refractory myelodysplastic syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for relapsed or refractory myelodysplastic syndrome. Targeted therapies are gaining prominence in the pipeline due to their mutation-specific approach. For instance, ivosidenib, an isocitrate dehydrogenase-1 inhibitor, is approved for patients with susceptible IDH1 mutations. It selectively inhibits mutant enzymes, restoring normal cellular differentiation and improving hematologic outcomes.

Relapsed or Refractory Myelodysplastic Syndrome Clinical Trials – Key Players

The EMR report for the relapsed or refractory myelodysplastic syndrome pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed relapsed or refractory myelodysplastic syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in relapsed or refractory myelodysplastic syndrome clinical trials:

• GluBio Therapeutics Inc.
• Nkarta, Inc.
• AbbVie
• ARCE Therapeutics, Inc.
• Cullgen (Shanghai), Inc.
• Foghorn Therapeutics Inc.
• Precigen, Inc.
• Remix Therapeutics
• Cullinan Therapeutics Inc.
• BlossomHill Therapeutics
• Edgewood Oncology Inc.
• Bristol-Myers Squibb

Relapsed or Refractory Myelodysplastic Syndrome – Emerging Drugs Profile

Key Questions Answered in the Relapsed or Refractory Myelodysplastic Syndrome Pipeline Insight Report

• Which companies/institutions are leading the relapsed or refractory myelodysplastic syndrome drug development?
• Which company is leading the relapsed or refractory myelodysplastic syndrome pipeline development activities?
• What is the current relapsed or refractory myelodysplastic syndrome commercial assessment?
• What are the opportunities and challenges present in the relapsed or refractory myelodysplastic syndrome pipeline landscape?
• What is the efficacy and safety profile of relapsed or refractory myelodysplastic syndrome pipeline drugs?
• Which company is conducting major trials for relapsed or refractory myelodysplastic syndrome drugs?
• Which companies/institutions are involved in relapsed or refractory myelodysplastic syndrome collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in relapsed or refractory myelodysplastic syndrome?

Reasons To Buy This Report

The Relapsed or Refractory Myelodysplastic Syndrome Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for relapsed or refractory myelodysplastic syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into relapsed or refractory myelodysplastic syndrome collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Myelodysplastic Syndrome Drug Pipeline Analysis Report